Brand Name | Status | Last Update |
---|---|---|
kaletra | New Drug Application | 2023-07-06 |
lopinavir and ritonavir | ANDA | 2023-10-20 |
lopinavir-ritonavir | ANDA | 2020-11-18 |
norvir | New Drug Application | 2024-07-03 |
paxlovid | New Drug Application | 2025-07-09 |
ritonavir | ANDA | 2025-06-05 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Dasabuvir Sodium / Ombitasvir / Paritaprevir / Ritonavir, Viekira Xr, Abbvie | |||
9333204 | 2035-01-02 | DP | U-1889 |
9744170 | 2035-01-02 | DP | U-1889 |
10105365 | 2035-01-02 | DP | U-1889 |
10201541 | 2032-05-17 | DP | |
10201584 | 2032-05-17 | U-1889 | |
Dasabuvir Sodium / Ombitasvir / Paritaprevir / Ritonavir, Viekira Pak (Copackaged), Abbvie | |||
9629841 | 2033-10-18 | DP | U-1753 |
10201542 | 2033-10-18 | DP | U-1753 |
8466159 | 2032-09-04 | U-1637 | |
8492386 | 2032-09-04 | U-1840 | |
8680106 | 2032-09-04 | U-1637 | |
8685984 | 2032-09-04 | U-1840 | |
8691938 | 2032-04-13 | DS, DP | |
8686026 | 2031-06-09 | DP | |
8420596 | 2031-04-10 | DS, DP | |
9044480 | 2031-04-10 | U-1638 | |
9006387 | 2030-06-10 | U-1687 | |
8642538 | 2029-09-10 | DS, DP | U-1638 |
8188104 | 2029-05-17 | DS, DP | U-1636 |
8501238 | 2028-12-19 | DS, DP | U-1636 |
9139536 | 2028-11-09 | U-1753 | |
8268349 | 2024-08-25 | DP | |
8399015 | 2024-08-25 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 91 | 153 | 153 | 130 | 109 | 602 |
Infections | D007239 | EFO_0000544 | — | 17 | 37 | 57 | 22 | 25 | 154 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 21 | 33 | 43 | 30 | 31 | 153 |
Hepatitis c | D006526 | — | B19.2 | 22 | 42 | 43 | 13 | 29 | 141 |
Hepatitis | D006505 | — | K75.9 | 14 | 49 | 44 | 7 | 29 | 136 |
Covid-19 | D000086382 | — | U07.1 | 11 | 41 | 43 | 11 | 41 | 128 |
Hiv | D006678 | — | O98.7 | 22 | 17 | 26 | 40 | 18 | 119 |
Hepatitis a | D006506 | EFO_0007305 | B15 | 7 | 39 | 41 | 6 | 26 | 113 |
Healthy volunteers/patients | — | — | — | 98 | 2 | — | 7 | 4 | 111 |
Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 6 | 36 | 35 | 9 | 22 | 103 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 4 | 14 | 14 | — | 2 | 31 |
Virus diseases | D014777 | — | B34 | — | 5 | 9 | — | 3 | 16 |
Fibrosis | D005355 | — | — | — | 3 | 8 | — | 2 | 12 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 3 | 6 | — | 3 | 11 |
Chronic hepatitis d | D019701 | — | — | — | 7 | 2 | — | — | 9 |
Hepatitis d | D003699 | EFO_0007304 | — | — | 7 | 2 | — | — | 9 |
Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | 2 | 3 | — | 3 | 7 |
Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | 1 | 2 | 1 | — | 3 | 6 |
Hyperlipoproteinemias | D006951 | — | — | 1 | 1 | 1 | — | — | 3 |
Respiratory tract infections | D012141 | — | J06.9 | 1 | — | 2 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 8 | 3 | — | — | — | 10 |
Liver diseases | D008107 | EFO_0001421 | K70-K77 | 4 | 1 | — | — | — | 5 |
Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | 1 | — | — | 3 | 4 |
Prostatic neoplasms | D011471 | — | C61 | 3 | 1 | — | — | — | 4 |
Coronavirus | D017934 | — | — | — | 1 | — | — | 2 | 3 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | — | — | — | 3 |
Immunocompromised host | D016867 | — | D84.9 | — | 1 | — | — | 2 | 3 |
Glioblastoma | D005909 | EFO_0000515 | — | 1 | 2 | — | — | — | 2 |
Disease | D004194 | EFO_0000408 | R69 | — | 2 | — | — | — | 2 |
Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pharmacokinetics | D010599 | — | — | 4 | — | — | — | 1 | 5 |
Hepatic insufficiency | D048550 | — | — | 5 | — | — | — | — | 5 |
Biological availability | D001682 | — | — | 5 | — | — | — | — | 5 |
Hypertension | D006973 | EFO_0000537 | I10 | 2 | — | — | — | 1 | 3 |
Pulmonary arterial hypertension | D000081029 | — | — | 2 | — | — | — | 1 | 3 |
Insulin resistance | D007333 | EFO_0002614 | E88.819 | 2 | — | — | — | 1 | 3 |
Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | 1 | 2 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | — | — | — | — | 2 |
Liver failure | D017093 | — | K72.9 | 2 | — | — | — | — | 2 |
Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 2 | 2 |
Female genital diseases | D005831 | EFO_0009549 | N85 | — | — | — | — | 1 | 1 |
Genital diseases | D000091662 | — | — | — | — | — | — | 1 | 1 |
Wasting syndrome | D019282 | — | — | — | — | — | — | 1 | 1 |
Cachexia | D002100 | — | R64 | — | — | — | — | 1 | 1 |
Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 1 | 1 |
Drug common name | Ritonavir |
INN | ritonavir |
Description | Ritonavir is an L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver. It has a role as an antiviral drug, a HIV protease inhibitor, an environmental contaminant and a xenobiotic. It is a member of 1,3-thiazoles, a L-valine derivative, a carbamate ester, a member of ureas and a carboxamide. |
Classification | Small molecule |
Drug class | antivirals: HIV protease inhibitors (saquinavir type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1 |
PDB | — |
CAS-ID | 155213-67-5 |
RxCUI | — |
ChEMBL ID | CHEMBL163 |
ChEBI ID | 45409 |
PubChem CID | 392622 |
DrugBank | DB00503 |
UNII ID | O3J8G9O825 (ChemIDplus, GSRS) |